Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This study is designed to confirm the non-inferiority of Tegoprazan 25 mg, compared to
Lansoprazole 15 mg, to prevent gastroduodenal ulcers and verify the safety of tegoprazan
following oral administration of tegoprazan 25 mg QD or lansoprazole 15 mg QD in patients on
long-term treatment with NSAIDs.